Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.38 |
| ▸ | UBE2M | P61081 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12081174 | 0.96 | HTR2A (0.35) | DCUN1D1UBE2MHTR2ARIPK1KCNH2 | |
| SCHEMBL2799351 | 0.87 | PIK3CA (0.37) | HTR2AKCNH2CYP1A2HTR2CCYP2C19 | |
| SCHEMBL909709 | 0.83 | UBE2M (0.40) | DCUN1D1UBE2MHTR2AKCNH2CHRNA7 | |
| SCHEMBL2799356 | 0.83 | UBE2M (0.34) | DCUN1D1UBE2MHTR2AKCNH2CHRNA7 | |
| SCHEMBL10313839 | 0.83 | PIK3CA (0.36) | HTR2AKCNH2CYP1A2HTR2CCYP2C19 | |
| SCHEMBL5036967 | 0.81 | UBE2M (0.52) | DCUN1D1UBE2MPKM | |
| SCHEMBL2767755 | 0.80 | KDM4E (0.37) | DCUN1D1KCNH2CHRNA7 | |
| SCHEMBL2797603 | 0.80 | KCNH2 (0.50) | KCNH2 | |
| Water SCHEMBL3517045 | 0.79 | KDM4E (0.37) | DCUN1D1KCNH2 | |
| SCHEMBL3515920 | 0.79 | CHRM2 (0.53) | DCUN1D1UBE2MPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | DCUN1D1 1635/4885UBE2M 826/4885HTR2A 4099/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | DCUN1D1 733/4885UBE2M 3579/4885HTR2A 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.